Abstract
Title Evaluation of Complications Associated with Hypertonic Saline versus Mannitol in the Management of Intracranial Hypertension and Their Mitigation Strategies: A Systematic Review
Background Intracranial hypertension (ICH) worsens outcomes in patients with traumatic brain injury (TBI) or post- neurosurgical conditions. Hyperosmolar agents, particularly mannitol and hypertonic saline (HTS), are widely used to reduce intracranial pressure (ICP), but their safety profiles remain debated. This systematic review aimed to compare complications and mitigation strategies associated with mannitol and HTS in managing elevated ICP.
Methods Eligible studies included randomized controlled trials (RCTs), cohort, and case-control studies from 2020 onward that reported complications related to mannitol or HTS in TBI or post-craniotomy patients. A comprehensive search was conducted in PubMed, Scopus, and Web of Science (last search February 17, 2025). Risk of bias was assessed using the Cochrane ROB2 and ROBINS-I tools. Due to heterogeneity in design and outcomes, a narrative synthesis was performed.
Results Seven studies (3 RCTs, 4 observational) involving 14,367 patients were included. HTS was associated with fewer complications including reduced risks of electrolyte imbalance, acute kidney injury (AKI), and hemodynamic instability compared to mannitol. Mannitol was linked to hyponatremia, hypotension, and transient reductions in cardiac output, particularly in elderly or renally impaired patients. Mortality and ICU stay duration were generally comparable, though HTS showed potential ICU survival benefit. Evidence certainty ranged from low to moderate, with risk of bias and small sample sizes affecting confidence.
Discussion HTS may offer a safer alternative to mannitol in patients at risk of renal or cardiac complications, with similar efficacy in ICP control. Mannitol remains effective but requires intensive monitoring. These findings support tailored use based on patient comorbidities and hemodynamic stability. For Iranian neurosurgical centers, where ICU bed shortages and cost constrains are prevalent, HTS’s renal safety profile and reduced cardiac strain in elderly patients could optimize resource utilization, a consideration absent in Western guidelines.
Funding No external funding was declared for this review.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
